Whole Genome And Exome Sequencing Market Report 2026

Whole Genome And Exome Sequencing Market Overview

• Whole Genome And Exome Sequencing market size has reached to $2.52 billion in 2025 • Expected to grow to $7.63 billion in 2030 at a compound annual growth rate (CAGR) of 24.8% • Growth Driver: Rising Demand For Personalized Medicines Driving The Growth Of The Market Due To Increasing Demand For Tailored Therapies • Market Trend: Key Player Introducing Ultra-Fast NGS Solutions to Transform Whole Genome and Exome Sequencing Markets • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Whole Genome And Exome Sequencing Market?

Whole genome sequencing (WGS) and exome sequencing (ES) are comprehensive genetic analysis techniques that involve determining the complete DNA sequence of an organism's genome and sequencing the protein-coding regions of the genome. These analyses are used to sequence a person's DNA for diagnosing genetic diseases and identifying cancer mutations. The main types of products included in whole genome and exome sequencing are kits and instruments. A kit is a grouping of separate but related products that ship in the same box, making inventory management and tracking easier. Various types of workflows include whole genome sequencing (WGS) and whole exome sequencing (WES), which are used for several applications, including diagnostics, cancer, monogenic disorders, diabetes, drug discovery and development, personalized medicine, agriculture and animal research, and others. Several end users include research centers, academic and government institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and others.

What Is The Whole Genome And Exome Sequencing Market Growth Forecast?

The whole genome and exome sequencing market size is expected to see exponential growth in the next few years. It will grow to $7.63 billion in 2030 at a compound annual growth rate (CAGR) of 24.8%. The growth in the forecast period can be attributed to increasing deployment of large-scale genomics projects, rising integration of ai in genomic analysis, expansion of clinical genomics adoption, growing investments in sequencing infrastructure, increasing demand for personalized treatment strategies. Major trends in the forecast period include increasing adoption of comprehensive genome sequencing, rising use of sequencing in oncology diagnostics, growing demand for integrated wgs and wes workflows, expansion of population genomics studies, enhanced focus on high-throughput sequencing platforms.

What Is The Driver Of The Whole Genome And Exome Sequencing Market?

The rising demand for personalized medicine is expected to propel the growth of the whole genome and exome sequencing market in the future. Personalized medicine is an approach to medical treatment that tailors healthcare decisions and interventions to the individual characteristics of each patient, considering factors such as genetics, environment, and lifestyle. Whole genome and exome sequencing is used in personalized medicine by providing a comprehensive analysis of an individual's genetic makeup, allowing for tailored healthcare decisions and interventions based on their unique genetic, environmental, and lifestyle factors. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based organization promoting the understanding and adoption of personalized medicine, 26 personalized medicines were approved by the FDA, including 20 new molecular entities (NMEs) and 6 gene-/cell-based therapies, representing roughly 38% of all newly approved therapeutic NMEs. Therefore, the rising demand for personalized medicine are driving the growth of the whole genome and exome sequencing industry.

Key Players In The Global Whole Genome And Exome Sequencing Market

Major companies operating in the whole genome and exome sequencing market are Siemens AG, Hoffmann‑La Roche Ltd., Thermo Fisher Scientific Inc., Cytiva (Danaher Corporation), Laboratory Corporation of America Holdings, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V, BGI Genomics, Novogene Co., Oxford Nanopore Technologies Inc., Pacific Biosciences of California Inc., GENEWIZ Inc., 10x Genomics Inc., MGI Tech Co. Ltd., Clear Labs Inc., Macrogen Inc., PierianDx Inc., Invitae Corporation, Fulgent Genetics Inc., SOPHiA GENETICS SA, Azenta US Inc., Gene by Gene Ltd.

Global Whole Genome And Exome Sequencing Market Trends and Insights

Major companies operating in the whole genome and exome sequencing markets are increasing their focus on developing advanced technological solutions, such as ultra-fast NGS (next-generation sequencing) analysis, to gain a competitive edge in the market. Ultra-fast NGS analysis is a technological innovation that enables the processing of next-generation sequencing (NGS) data at an exceptionally high speed, significantly reducing the time required for genomic data analysis. For instance, in January 2023, QIAGEN Digital Insights (QDI), a US-based bioinformatics company, launched the ultra-fast NGS analysis platform. This platform offers features such as processing a whole genome in 25 minutes for $1 in cloud computing costs, promoting efficiency, affordability, and scalability; its technological innovation significantly enhances genomic data analysis speed and accessibility, thus holding considerable importance in the whole genome and exome sequencing market by enabling rapid decision-making and wider adoption of personalized medicine.

What Are Latest Mergers And Acquisitions In The Whole Genome And Exome Sequencing Market?

In January 2023, QIAGEN, a Germany-based global company that provides sample technologies and products for molecular insights, acquired Verogen for an undisclosed amount. This acquisition enhances QIAGEN's capabilities in the human ID or forensics market, strengthening leadership and fostering the development of more comprehensive solutions with potentially far-reaching impacts on the whole genome and exome sequencing market. Verogen is a US-based biotech provider of NGS tools and services, encompassing whole genome and exome sequencing.

What Defines the Whole Genome And Exome Sequencing Market?

The whole genome and exome sequencing market consists of revenues earned by entities by providing services such as genetic profiling, variant identification, personalized medicine solutions, and comprehensive genomic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The whole genome and exome sequencing market also includes sales of exome capture kits, benchtop sequencer, and sample preparation instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Whole Genome And Exome Sequencing Market Report 2026?

The whole genome and exome sequencing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the whole genome and exome sequencing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.